Philippe Soubeyran obtained his PhD from the Aix-Marseille University in 2000. At this time, his work was dedicated to the study of two homeotic genes, CDX1 and CDX2, involved in gut development and under-expressed in colon cancers. From 2000 to 2003, he worked as a postdoc at the Ludwig Institute for Cancer Research of Uppsala (Sweden) in the group of Prof. Ivan Dikic. The main goals of this training was to decipher the role of two scaffold proteins, CIN85 and ArgBP2, in the transduction and regulation of cell signaling. In 2005, he was recruited by the French National Institute for Health and Medical Research (INSERM) to work as a principal investigator in the Cellular Stress laboratory, from 2005 to 2012. Since 2012, he is a member of the Pancreatic Cancer team of CRCM (Cancer Research Center of Marseille). His current projects are dedicated to the identification of new resistance mechanisms of pancreatic cancer cells involving alterations of post-translational modifications of ubiquitin-like type.